VERTEX PHARMACEUTICALS INC / MA Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $17.38 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-11.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2020 was $17.38M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2019 was -$2.67M.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2018 was -$1.56B.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2017 was -$575.80M, a 3980.85% decline from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month as first filed |
|---|---|---|
| 2020-12-31 | $17.38M 10-K · filed 2021-02-11 | |
| 2019-12-31 | -$2.67M 10-K · filed 2021-02-11 | |
| 2018-12-31 | -$1.56B 10-K · filed 2021-02-11 | |
| 2017-12-31 | -$575.80M 10-K · filed 2020-02-13 | -$584.92M 10-K · filed 2018-02-15 |
| 2016-12-31 | $14.84M 10-K · filed 2019-02-13 | $14.80M 10-K · filed 2017-02-23 |
| 2015-12-31 | $226.17M 10-K · filed 2018-02-15 | $306.40M 10-K · filed 2016-02-16 |
| 2014-12-31 | -$166.30M 10-K · filed 2015-02-13 | |
| 2013-12-31 | -$32.10M 10-K · filed 2014-02-11 | |
| 2012-12-31 | -$118.20M 10-K · filed 2013-03-01 | |
| 2011-12-31 | $38.40M 10-K · filed 2012-02-22 | |
| 2010-12-31 | $287.00M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |